

ORIGINAL ARTICLE

LL-Z1272 α epoxide, a precursor of ascochlorin produced by a mutant of *Ascochyta viciae*

Kuniaki Hosono¹, Jun Ogihara¹, Takamichi Ohdake¹ and Setsuko Masuda²

A novel metabolite, LL-Z1272 α epoxide, structurally related to ascochlorin, was isolated from the cultured mycelium of *Ascochyta viciae* J-29, a mutant derived from *A. viciae* Libert. The structure was elucidated on the basis of spectroscopic data. The epoxide is proposed to be enzymatically formed from LL-Z1272 α and is a precursor of ascochlorin, an antiviral and antitumor antibiotic. The conversion of the epoxide to ascochlorin by cyclization of its farnesyl chain to a cyclohexanone ring is similar to that of squalene 2, 3-oxide to sterols. Unlike ascochlorin, the new metabolite had no growth inhibitory activity against *Candida albicans* in the paper-disc agar diffusion assay.

The Journal of Antibiotics (2009) 62, 571–574; doi:10.1038/ja.2009.80; published online 14 August 2009

Keywords: ascochlorin precursor; fungal metabolite; LL-Z1272 α epoxide; prenylphenol antibiotic

INTRODUCTION

Ascochlorin was originally isolated as an antiviral agent from the filter cake of the fermented broth of *Ascochyta viciae* Libert¹ (Figure 1), and ascofuranone was similarly isolated as an antiviral compound from the same strain.² Subsequently, many structurally related compounds have been isolated from various fungi such as an unclassified *Fusarium* species LL-Z1272,³ *Cylindrocladium* sp.,⁴ *Cylindrocladium ilicicola* MFC-870,⁵ *Nectria coccinea*,⁶ *Colletotrichum nicotianae*,⁷ *Acremonium luzulae*,⁸ *Cephalosporium diospyri*,⁹ *Verticillium* sp. FO-2787,¹⁰ *Cylindrocarpon lucidum*,¹¹ *Nigrosabulum globosum*¹² and the insect pathogenic fungus *Verticillium hemipterigenum* BCC 2370.¹³

Ascochlorin and its derivatives exhibit a large variety of physiological activities, including hypolipidemic activity,¹⁴ suppression of hypertension,¹⁵ amelioration of type I and II diabetes,¹⁶ antitumor activity¹⁷ and immunomodulation.¹⁸

Although ascochlorin and structurally related compounds have been isolated from diverse fungi and have been reported to have wide biological activities, their biosynthetic pathway has been uncertain. It has been proposed that the farnesyl chain of LL-Z1272 α (Figure 1) is epoxidized, cyclized to a cyclohexanone ring and converted to ascochlorin just as in the case of the enzymatic conversion of squalene 2, 3-oxide to lanosterol and cholesterol.³ However, this epoxide, the expected intermediate to which the farnesyl chain with a terminal double bond is converted, has not been isolated hitherto.

By screening metabolites produced by more than 2000 mutants of *A. viciae*, we found a new compound related to ascochlorin. The structure was elucidated to be LL-Z1272 α epoxide on the basis of spectroscopic data. In this report, we describe the isolation and structure of this epoxide (Figure 1) and discuss the biosynthesis of ascochlorin.

RESULTS

Physico-chemical properties of LL-Z1272 α epoxide

LL-Z1272 α epoxides are crystals with a pale yellow color; Mp: 38–39 °C; $[\alpha]_D^{25.4} = +6.6$ (*c* 0.5, CHCl₃); high resolution fast atom bombardment mass spectrum (HRFAB-MS) m/z 407.1941 [M+H]⁺ (calculated for C₂₃H₃₂ClO₄, 407.1989); UV (MeOH) λ_{\max} (ϵ) 227 (17 000) and 293 (12 900) nm; IR (KBr) ν_{\max} 3384, 2984–2834, 1617, 1279, 1243 cm⁻¹. The ¹H-NMR and ¹³C-NMR assignments of LL-Z1272 α epoxide are listed in Table 1.

Structure elucidation

The LL-Z1272 α epoxide was obtained as crystals with a pale yellow color. Its formula was determined to be C₂₃H₃₁ClO₄ on the basis of HRFAB-MS at m/z 407.1941 [M+H]⁺ (calculated for C₂₃H₃₂ClO₄, 407.1989). IR absorptions at 3384 (OH), 2984–2834 (methyl, methylene and methine), 1617 (CO), 1279 (CO) and 1243 (CO) cm⁻¹ were observed. UV spectral absorptions at λ_{\max} (ϵ) 227 (17 000) and 293 (12 900) nm were obtained. The ¹³C-NMR spectrum (CDCl₃) showed 23 resolved peaks, which were classified into 5 *sp*³ methyls (δ_c 14.5, 16.2, 16.0, 23.4 and 26.5), 5 *sp*³ methylenes (δ_c 22.1, 39.6, 26.2, 36.8 and 36.8), 1 *sp*³ methine (δ_c 78.3), 2 *sp*² methines (δ_c 121.3 and 125.0), 1 *sp*³ oxygenated quaternary carbon atom (δ_c 73.1), 8 *sp*² quaternary carbon atoms (δ_c 113.7, 162.2, 114.5, 156.5, 113.4, 137.7, 136.5 and 135.0) and 1 carbonyl group (δ_c 193.3). Its ¹H-NMR spectral data revealed the signal of one aldehyde proton (1-CHO, δ_H 10.13), one *sp*³ methyl attached to the aromatic ring (6-CH₃, δ_H 2.59), four *sp*³ methyl groups (δ_H 1.77, 1.59, 1.15 and 1.19), one *sp*³ methine (δ_H 3.35), two *sp*² methines (δ_H 5.19 and 5.15) and five *sp*³ methylenes (δ_H 3.39, 2.01, 2.09, 2.06 and 2.19).

¹Department of Applied Biological Science, College of Bioresource Sciences, Nihon University, Kameino, Fujisawa, Japan and ²NRL Pharma, KSP, Takatsu-ku, Kawasaki, Japan
Correspondence: Dr K Hosono, Department of Applied Biological Science, College of Bioresource Sciences, Nihon University, Kameino 1866, Fujisawa, Kanagawa 252-8510, Japan.

E-mail: khosono@brs.nihon-u.ac.jp

Received 1 June 2009; revised and accepted 22 July 2009; published online 14 August 2009




Figure 1 Structures of ascochlorin, LL-Z1272 α , and LL-Z1272 α epoxide.

Table 1 NMR spectral data on LL-Z1272 α epoxide in CDCl₃

No.	δ_H (J in Hz)	δ_C (Hz)	HMBC
1		113.7	
2		162.2	
3		114.5	
4		156.5	
5		113.4	
6		137.7	
7	3.39 (2H, d, $J=6.9$)	22.1	2, 3, 4, 8, 9
8	5.19 (1H, t, $J=6.9$)	121.3	7, 10, 9-CH ₃
9		136.5	
10	2.01 (2H, m)	39.6	9, 11, 12
11	2.09 (2H, m)	26.2	10, 12, 13
12	5.15 (1H, t, $J=6.5$)	125.0	14
13		135.0	
14	2.06 (2H, m)	36.8	
15	2.19 (2H, m)	36.8	
16	3.35 (1H, d, $J=10.3$)	78.3	
17		73.1	
1-CHO	10.13 (1H, s)	193.3	1, 2, 3
6-CH ₃	2.59 (3H, s)	14.5	1, 5, 6
9-CH ₃	1.77 (3H, s)	16.2	8, 9, 10
13-CH ₃	1.59 (3H, s)	16.0	12, 13, 14
17-CH ₃	1.15 (3H, s)	23.4	16, 17, 17-CH ₃ '
17-CH ₃ '	1.19 (3H, s)	26.5	16, 17, 17-CH ₃

Alignments of vicinal protons and carbons were determined by carrying out ¹H–¹H COSY and heteronuclear multiple bond correlation (HMBC) experiments. ¹H–¹H COSY experiments revealed correlations from 7-H to 9-CH₃ through to 8-H, and from 10-H to




Figure 2 Selected ¹H–¹H COSY and heteronuclear multiple bond correlation (HMBC) correlations for LL-Z1272 α epoxide.

16-H through to 11-H, 12-H, 13-CH₃, 14-H and 15-H, as indicated by the bold-faced lines in Figure 2. Assignments of the signals for nine quaternary carbons (C-1, C-2, C-3, C-4, C-5, C-6, C-9, C-13 and C-17) were revealed by HMBC experiments. The long-range couplings from the aldehyde proton 1-CHO to C-1, C-2 and C-3; from the methyl proton 6-CH₃ to C-1, C-5 and C-6; from the methylene proton 7-H to C-2, C-3, C-4, C-8 and C-9; from the methine proton 8-H to C-7, 9-CH₃ and C-10; from the methyl proton 9-CH₃ to C-8, C-9 and C-10; from the methylene proton 10-H to C-9, C-11 and C-12; from the methylene proton 11-H to C-10, C-12 and C-13; from the methine proton 12-H to C-14; from the methyl proton 13-CH₃ to C-12, C-13 and C-14; from the methyl proton 17-CH₃ to C-16, C-17 and 17-CH₃'; and from the methyl proton 17-CH₃' to C-16, C-17 and 17-CH₃ were confirmed from HMBC spectra (Table 1).

In differential NOE experiments, the correlations among 8-H, 7-H and 10-H, and among 7-H, 9-CH₃ and 13-CH₃ were observed, and the stereochemistry of the double bond at C-8 was deduced to be *E*. Similarly, the correlations among 12-H, 11-H and 14-H, and among 9-CH₃, 13-CH₃ and 17-CH₃, established the stereochemistry of the double bond at C-12 to be *E*. The presence of a chlorine was shown using HRFAB-MS analysis, and the connection of its atom to C-5 was reasonable from its chemical shift (δ_c 113.4).

Biological activity

It is reported that ascochlorin inhibits the growth of yeast *C. albicans*, in addition to having antiviral activity.¹ Ascochlorin at a concentration of 5 mg ml⁻¹ (12.4 mM) caused a clear growth inhibitory zone (ϕ 14 mm) when tested against *C. albicans* NBRC 1386 in the paper-disc agar diffusion assay, but no such zone appeared with LL-Z1272 α epoxide at a concentration of 12.3 mM. The diameter of the paper disc was 8 mm.

DISCUSSION

The parent strain, *A. viciae* Libert, concurrently produces both ascochlorin and ascofuranone.² There are many structurally related compounds with various biological activities (see Introduction), but studies on their biosyntheses have not been reported yet. We obtained mutants that produced LL-Z1272 α and/or LL-Z1272 α epoxide, which is likely to be a precursor of ascochlorin. Mutant J-15 produced LL-Z1272 α only (unpublished data), whereas mutant J-29 produced LL-Z1272 α epoxide, together with ascofuranone (in this report). Both ascochlorin and LL-Z1272 α have been isolated together from *Fusarium* species,³ *Nectria coccinea*⁶ and *Verticillium* sp.¹⁰ Ellestad *et al.*³ proposed that the farnesyl chain of LL-Z1272 α was epoxidized, cyclized to a cyclohexanone ring and converted to ascochlorin




Figure 3 Pathway for the biosynthesis of ascochlorin.

(Figure 3), just as in the case of the enzymatic conversion of squalene 2, 3-oxide to lanosterol and cholesterol.¹⁹ However, the expected intermediate to which the farnesyl chain with a terminal double bond was converted, had not been previously isolated. The isolation of LL-Z1272 α epoxide supports the hypothesis of Ellestad *et al.*, with the epoxide being converted into ascochlorin similarly as squalene oxide is converted into sterols. Thus, we are convinced that LL-Z1272 α epoxide is a precursor of ascochlorin. Mutant J-29 produced the epoxide along with ascofuranone in an amount that was approximately one-half of that of the epoxide, suggesting that the activity of converting the epoxide to ascochlorin was severely blocked in the mutant and that the conversion into ascofuranone was less obstructed in it. If there were these branching pathways from the LL-Z1272 α epoxide, the yield amounts of ascochlorin and ascofuranone might roughly correspond to the activity of each of the converting enzymes. In the future, it will be necessary to verify whether LL-Z1272 α is converted into its epoxide by a specific enzyme and then to investigate whether the epoxide is converted into ascochlorin and ascofuranone separately by different branches of the biosynthetic pathway.

METHODS

Mutation and isolation of mutants

A. viciae Libert isolated from soil¹ was used as the parent strain and was maintained on a malt extract-yeast extract (MY) agar medium composed of glucose 1%, polypeptone 0.5%, yeast extract 0.3% and malt extract 0.3% at pH 6 in agar 1.8%. The strain grown on the MY agar medium at 28 °C for 7 days was harvested by centrifugation at 7300 *g* for 10 min and was washed once with 0.9% (w/v) NaCl solution. The short mycelial cells were suspended in the saline containing *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (NTG) at a final concentration of 10, 30 or 100 $\mu\text{g l}^{-1}$. After each cell suspension had been incubated with one of the above concentrations of NTG for 60 min at 28 °C, the cell was harvested by centrifugation, washed twice with saline, suspended in MY medium and incubated at 28 °C with gentle shaking for 2 h. Each cell suspension was appropriately diluted with saline and spread on the MY agar medium. After incubation at 28 °C for 7 days, a single colony from the colonies that appeared on the medium was transferred to the MY agar medium and




Figure 4 HPLC profiles of metabolites produced by *A. viciae* Libert and mutant J-29 monitored at 295 nm.

maintained. About 400 mutant colonies were isolated with a certain concentration of NTG. For screening, the isolated fungal mutant was cultured in a thick test tube (ϕ 25 mm \times 20 cm) containing 20 ml of production medium (see following part), and the mycelium of each mutant strain was extracted with four volumes of MeOH to analyze for the presence of new metabolites. The production of new metabolites was monitored by HPLC. Each mutant that produced new ascochlorin-related compounds was repeatedly treated with different concentrations of NTG to generate further mutants that produced larger quantities of the new metabolites. The mutant J-29 was finally obtained after the parent strain had been mutated with successive concentrations of 10, 100, 100, 30 and 100 $\mu\text{g l}^{-1}$ NTG. Therefore, the mutant J-29 was selected from more than 2000 colonies.

Fermentation of *A. viciae* mutant J-29

For production of LL-Z1272 α epoxide, the mutant J-29 was cultured in production medium composed of glucose 7.0%, polypeptone 0.3%, yeast extract 0.2%, KH_2PO_4 0.05%, $\text{MgSO}_4\cdot 7\text{H}_2\text{O}$ 0.05%, corn steep liquor 0.1%, $(\text{NH}_4)_2\text{SO}_4$ 0.1%, $\text{CaCl}_2\cdot 2\text{H}_2\text{O}$ 0.2%, CH_3COONa 0.5%, CaCO_3 0.1% and one drop of Adekanol LG-109 (anti-foaming agent; Adeka, Tokyo, Japan). The fungus was aerobically cultured at 28 °C for 7 days in a 500-ml Erlenmeyer flask containing 50 ml of the production medium.

HPLC analysis

To analyze the fungal products of isolated mutant strains, we cultured each mutant at 28 °C for 7 days in a 500-ml Erlenmeyer flask containing 50 ml of production medium. The mycelium of each mutant was harvested by centrifugation at 7300 *g* for 10 min and extracted with four volumes of MeOH. The extract was concentrated under reduced pressure and dissolved in a small amount of MeOH for analysis of products using a Shimadzu HPLC system, Model LC-VP (Shimadzu, Kyoto, Japan), equipped with an ODS column (YMC-Pack ODS-A302; 150 \times 4.6 mm i.d.; YMC, Kyoto, Japan). The column was maintained at 40 °C and eluted isocratically with a mixture of acetonitrile–isopropyl alcohol– H_2O –acetic acid (350:200:450:2, v/v) at a flow rate of 2.0 ml min^{-1} . A small portion of the MeOH extract was subjected to HPLC using an automatic injection system, and separation was monitored at 295 nm. Representative HPLC chromatograms are shown in Figure 4. Ascochlorin and ascofuranone were determined by comparison with authentic compounds.

Isolation and purification of LL-Z1272 α epoxide

The mutant J-29 was cultured in production medium (4500 ml) and its mycelium was extracted with four volumes of MeOH. The extract was concentrated *in vacuo* and dissolved in brine. Thereafter, ascochlorin and its structurally related compounds were extracted with EtOAc and concentrated *in vacuo*. The extract (3.52 g) was passed through a silica gel 60 column (ϕ 35 mm \times 13 cm) with a mixture of EtOAc and *n*-hexane (1:5, v/v). The

fraction eluted with the mixture of solvents (2.56 g) was passed again through another silica gel 60 column (φ 50 mm \times 26 cm), and four fractions, 1.35 g, 0.11 g, 0.74 g and 0.23 g, in the order eluted, were separated by the same mixture of EtOAc and *n*-hexane (1:5, v/v). The first fraction (1.35 g) was purified repeatedly by silica gel 60 column chromatography and was crystallized with difficulty. Finally, crystals with a pale yellow color (1.1 g) were obtained. From $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ analyses, the substance was elucidated to be LL-Z1272 α epoxide. The second and fourth fractions were not analyzed further. The third fraction (0.74 g) was identical to ascofuranone on the basis of comparison of $^1\text{H-NMR}$ spectra and the retention time of authentic ascofuranone on the HPLC chromatogram. After the fractions had been separated by silica gel 60 thin-layer chromatography with a mixture of EtOAc and *n*-hexane (1:5, v/v), the R_f values for ascochlorin, ascofuranone and LL-Z1272 α epoxide were calculated to be 0.19, 0.25 and 0.31, respectively.

Spectroscopic measurements

NMR spectra were recorded on a Jeol JNM-ECA 500 FT NMR system (Jeol, Tokyo, Japan), with $^1\text{H-NMR}$ at 500 MHz and $^{13}\text{C-NMR}$ at 125 MHz, using deuterated solvent (CDCl_3). The melting point value was uncorrected. UV spectra were recorded on a Shimadzu UV-160A spectrophotometer, and IR spectra were measured with a Jasco FT/IR-7300 spectrometer linked to a WS/IR-7300 workstation (Jasco, Tokyo, Japan). Mass spectra were recorded with a Jeol SX-102A spectrometer in the FAB mode by using glycerol as matrix and polyethylene glycol as the internal standard. Optical rotation values were recorded with a Jasco DIP-1000 polarimeter.

Inhibitory activity against *Candida albicans*

For determination of the inhibitory activity against *C. albicans* NBRC 1386, each solution of ascochlorin and LL-Z1272 α epoxide, with the same concentration of 5 mg ml $^{-1}$, was applied to a paper disc (φ 8 mm), and each paper disc was then placed onto YPD agar medium onto which *C. albicans* had been spread. The YPD medium was composed of yeast extract 1%, peptone 2% and glucose 2% at pH 7.2 in agar 1.8%.

ACKNOWLEDGEMENTS

We are very grateful to Dr K Ando for providing *A. viciae* Libert and authentic compounds, ascochlorin and ascofuranone. We also thank Dr H Kondo (NRL Pharma) for discussion on the isolation of the epoxide. This work was partially supported by a grant from the New Energy and Industrial Technology Development Organization (NEDO), Japan.

- 1 Tamura, G., Suzuki, S., Takatsuki, A., Ando, K. & Arima, K. Ascochlorin, a new antibiotic, found by paper-disc agar-diffusion method. I. Isolation, biological and chemical properties of ascochlorin (Studies on antiviral and antitumor antibiotics. I). *J. Antibiot.* **21**, 539–544 (1968).
- 2 Sasaki, H., Okutomi, T., Hosokawa, T., Nawata, Y. & Ando, K. Ascofuranone, a new antibiotic from *Ascochyta viciae*. *Tetrahedron Lett.* **25**, 2541–2544 (1972).
- 3 Ellestad, G. A., Evans, R. H. Jr & Kunstmann, M. P. Some new terpenoid metabolites from an unidentified *Fusarium* species. *Tetrahedron* **25**, 1323–1334 (1969).
- 4 Kato, A., Ando, K., Tamura, G. & Arima, K. Cylindrochlorin, a new antibiotic produced by *Cylindrocladium*. *J. Antibiot.* **23**, 168–169 (1970).
- 5 Hayakawa, S., Minato, H. & Katagiri, K. The ilicicolins, antibiotics from *Cylindrocladium ilicicola*. *J. Antibiot.* **24**, 653–654 (1971).
- 6 Aldridge, D. C. *et al.* Metabolites of *Nectria coccinea*. *J. Chem. Soc. [Perkin I]* **17**, 2136–2141 (1972).
- 7 Kosuge, Y., Suzuki, A., Hirata, S. & Tamura, S. Structure of colletochlorin from *Colletotrichum nicotianae*. *Agric. Biol. Chem.* **37**, 455–456 (1973).
- 8 Cagnoli-Bellavita, N., Ceccherelli, P., Fringuelli, R. & Ribaldi, M. Ascochlorin: a terpenoid metabolite from *Acremonium luzulae*. *Phytochemistry* **14**, 807 (1975).
- 9 Kawagishi, H., Sato, H., Sakamura, S., Kobayashi, K. & Uii, T. Isolation and structure of a new diprenyl phenol, colletorin B produced by *Cephalosporium diospyri*. *Agric. Biol. Chem.* **48**, 1903–1904 (1984).
- 10 Takamatsu, S. *et al.* A novel testosterone 5 α -reductase inhibitor, 8',9'-dehydroascochlorin produced by *Verticillium* sp. FO-2787. *Chem. Pharm. Bull.* **42**, 953–956 (1994).
- 11 Singh, S. B. *et al.* Chemistry and biology of cylindrols: novel inhibitors of Ras farnesyl-protein transferase from *Cylindrocarpon lucidum*. *J. Org. Chem.* **61**, 7727–7737 (1996).
- 12 Che, Y., Swenson, D. C., Gloer, J. B., Koster, B. & Malloch, D. Pseudodestruxins A and B: new cyclic depsipeptides from the coprophilous fungus *Nigrosabulum globosum*. *J. Nat. Prod.* **64**, 555–558 (2001).
- 13 Seephonkai, P., Isaka, M., Kittakoop, P., Boonudomplap, U. & Thebtaranonth, Y. A novel ascochlorin glycoside from the insect pathogenic fungus *Verticillium hemipterigenum* BCC 2370. *J. Antibiot.* **57**, 10–16 (2004).
- 14 Hosokawa, T., Sawada, M., Ando, K. & Tamura, G. Enhanced excretion of fecal neutral sterols and the hypocholesterolemic property of 4-*O*-methylascochlorin in mice. *Agric. Biol. Chem.* **44**, 2461–2468 (1980).
- 15 Hosokawa, T., Okutomi, T., Sawada, M., Ando, K. & Tamura, G. Unusual concentration of urine and prevention of polydipsia by fungal prenylphenols in DOCA hypertensive rats. *Eur. J. Pharmacol.* **69**, 429–438 (1981).
- 16 Hosokawa, T., Ando, K. & Tamura, G. An ascochlorin derivative, AS-6, potentiates insulin action in streptozotocin diabetic mice and rats. *Agric. Biol. Chem.* **46**, 2865–2869 (1982).
- 17 Magae, J., Hosokawa, T., Ando, K., Nagai, K. & Tamura, G. Antitumor protective property of an isoprenoid antibiotic, ascofuranone. *J. Antibiot.* **35**, 1547–1552 (1982).
- 18 Magae, J. *et al.* Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. *J. Antibiot.* **41**, 959–965 (1988).
- 19 Willett, J. D., Sharpless, K. B., Lord, K. E., van Tamelen, E. E. & Clayton, R. B. Squalene-2,3-oxide, an intermediate in the enzymatic conversion of squalene to lanosterol and cholesterol. *J. Biol. Chem.* **242**, 4182–4191 (1967).